.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,723,606

« Back to Dashboard

Claims for Patent: 5,723,606

Title: Condensed benzazepine derivative and pharmaceutical composition thereof
Abstract:This invention relates to nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivatives represented by the general formula (I) ##STR1## (symbols in the formula have the following meanings; ring B: a nitrogen-containing aromatic 5-membered ring having at least 1 nitrogen atom and optionally one oxygen or sulfur atom, which may optionally have substituent(s), R.sup.1 and R.sup.2 : these may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, an amino group which may optionally be substituted by lower alkyl group(s), or a lower alkoxy group, A: a single bond; a group represented by the formula n: 0 or an integer of from 1 to 3, R.sup.3 and R.sup.4 : these may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group (provided that R.sup.3 and R.sup.4 may together form a lower alkylene group having 2 to 7 carbon atoms), and ring C: a benzene ring which may optionally have substituent(s)) and salts thereof; to pharmaceutical compositions which contain these compounds as an active ingredient and to intermediates which are useful in synthesizing these compounds. The compounds of this invention are useful as arginine vasopressin antagonists.
Inventor(s): Tanaka; Akihiro (Ibaraki, JP), Koshio; Hiroyuki (Ibaraki, JP), Taniguchi; Nobuaki (Ibaraki, JP), Matsuhisa; Akira (Ibaraki, JP), Sakamoto; Ken-ichiro (Ibaraki, JP), Yamazaki; Atsuki (Ibaraki, JP), Yatsu; Takeyuki (Ibaraki, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/586,686
Patent Claims: 1. A nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative represented by the following formula (I) ##STR168## wherein the symbols in the formula (I) have the following meanings; ring B: a nitrogen-containing aromatic 5-membered ring having at least 1 nitrogen atom and optionally one oxygen or sulfur atom, which may optionally have substituent(s), R.sup.1, R.sup.2 : these may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, an amino group which may optionally be substituted by lower alkyl group(s), or a lower alkoxy group, A: a single bond or a group represented by the formula

n: 0 or an integer of from 1 to 3,

R.sup.3, R.sup.4 : these may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group provided that R.sup.3 and R.sup.4 may together form a lower alkylene group having 2 to 7 carbon atoms, and ring C: a benzene ring, which is substituted with a substituted or unsubstituted aryl group or a substituted or unsubstituted saturated or unsaturated heterocyclic group or a salt thereof.

2. The nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof according to claim 1 wherein

i) said ring B is a nitrogen-containing aromatic 5-membered ring having at least 1 nitrogen atom and optionally one oxygen or sulfur atom, which is represented by the formula: ##STR169## wherein the symbols in the formula have the following meanings; X.sup.1, X.sup.3 : one of them is a group represented by the formula .dbd.N--, and the other is a group represented by the formula --NR.sup.5 --, --O--, --S-- or --N--,

X.sup.2 : a group represented by the formula .dbd.CR.sup.6 --, --O--, --S-- or .dbd.N--,

R.sup.5 : a hydrogen atom or a lower alkyl group, and

R.sup.6 :

a) a hydrogen atom,

b) a lower alkyl, lower alkenyl or lower alkynyl group, which is unsubstituted or substituted by the following groups,

an amino group; a mono or di lower alkylamino group; a lower alkanoylamino group substituted by an amino group or a mono or di lower alkylamino group; a protected amino group; a 1-pyrrolidinyl group; a piperidino group; a morpholino group; a 1-piperazinyl, 1-imidazolidinyl, 1-homopiperazinyl or 1-pyrazolidinyl group, which may optionally be substituted by a lower alkyl group at the nitrogen atom of the ring; a guanidino group; an amidino group; a hydroxyl group; a lower alkoxyl group; a cyano group; a carbamoyl group; a carboxyl group; a lower alkoxycarbonyl group; a lower alkanoyloxy group; or a phenyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, pyrrolyl, tetrazolyl, triazolyl, thiazolyl or oxazolyl group, which may optionally be substituted by a lower alkyl group, a halogen atom, a lower alkoxyl group, an amino group, a mono or di lower alkylamino group, a hydroxyl group or a carboxyl group,

c) a cycloalkyl group having 3 to 8 carbon atoms,

d) an amino group; an amino group mono- or di-substituted by a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a lower alkanoyl group, where these groups may further be substituted by an amino group; a mono or di lower alkylamino group; a 1-pyrrolidinyl group; a piperidino group; a morpholino group; or a 1-piperazinyl, 1-imidazolidinyl or 1-homopiperazinyl group which may optionally be substituted by a lower alkyl group; a 1-pyrrolidinyl group; a piperidino group; a morpholino group; or a 1-piperazinyl, 1-imidazolidinyl 1-homopiperazinyl group which may optionally be substituted by a lower alkyl group at the nitrogen atom of the ring,

e) a guanidino group; an amidino group, or

f) a hydroxyl group, a lower alkoxyl group, a mercapto group, or a lower alkylthio group, and

ii) said ring C is a benzene ring which has one substituent selected from

a) a phenyl group which may optionally be substituted by a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a halogen atom, a lower alkoxy group, an amino group, a mono or di lower alkylamino group, a hydroxyl group or a carboxyl group, and

b) an imidazolyl, triazolyl, tetrazolyl, pyrrolyl, pyridyl, pyrazinyl or pyrimidinyl group, which may optionally be substituted by a lower alkyl group, a cycloalkyl group or a phenyl group.

3. The nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof according to claim 2 wherein one of X.sup.1 and X.sup.3 is a group represented by a formula .dbd.N-- and the other is a group represented by a formula --NR.sup.5 -- (R.sup.5 is the same group shown in claim 2), --O--, or --S--, and X.sup.2 is a group represented by a formula --CR.sup.6 -- (R.sup.6 is the same group shown in claim 2).

4. The nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof according to claim 3 wherein said ring B is a ring represented by the formula: ##STR170## (in this formula, R.sup.5 and R.sup.6 are respectively the same groups shown in claim 3).

5. The nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof according to claim 4 wherein

i) R.sup.6 is

a) a hydrogen atom,

b) a lower alkyl group which is unsubstituted or substituted by the following groups, an amino group; a mono or di lower alkylamino group; a lower alkanoylamino group substituted by an amino group or a mono or di lower alkylamino group; a 1-pyrrolidinyl group; a piperidino group; a morpholino group; a 1-piperazinyl group which may optionally be substituted by a lower alkyl group at the nitrogen atom of the ring; a guanidino group; an amidino group; or a phenyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, pyrrolyl, tetrazolyl or triazolyl group, which may optionally be substituted by a lower alkyl group,

c) a cycloalkyl group having 3 to 8 carbon atoms,

d) an amino group; or an amino group mono- or di-substituted by a lower alkyl group or a lower alkanoyl group wherein these groups may further be substituted by an amino group or a mono or di lower alkylamino group, or

e) a guanidino group, or an amidino group, and

ii) said ring C is a benzene ring which may optionally have a substituent at the o (ortho) position, the substituent being selected from a phenyl group which may optionally be substituted by a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a halogen atom, a lower alkoxy group, an amino group, a mono or di lower alkylamino group, a hydroxyl group or a carboxyl group; and an imidazolyl, triazolyl, tetrazolyl or pyrrolyl group which may optionally be substituted by a lower alkyl group.

6. The nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof according to claim 5 wherein said ring C is a benzene ring which is unsubstituted or substituted by a lower alkyl-substituted phenyl group.

7. The nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof according to claim 6 wherein R.sup.6 is

a) a hydrogen atom,

b) a lower alkyl group which is unsubstituted or substituted by the following groups,

an amino group; a mono or di lower alkylamino group; a morpholino group; a phenyl group; an imidazolyl group which may optionally be substituted by a lower alkyl group; or a pyridyl group,

c) a cyclopropyl group,

d) an amino group, a dimethylamino-substituted lower alkylamino group, an amino lower alkanoylamino group, or

e) a guanidino group.

8. A pharmaceutical composition which comprises as an active ingredient a pharmaceutically effective amount of a nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof as claimed in claim 1, and a pharmaceutically acceptable carrier or diluent.

9. A method of treating diseases impacted by arginine vasopressin comprising administering a therapeutically effective amount of an aromatic 5-membered ring-condensed benzazepine derivative or a salt thereof as claimed in claim 1 as an arginine vasopressin antagonist to a patient in need of the same.

10. 4'-[(2-Methyl- 1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzan ilide or a salt thereof.

11. 4'-[(2-Ethyl-1,4,5,6 -tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide or a salt thereof.

12. 4'-[(2-Cyclopro pyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbe nzanilide or a salt thereof.

13. 4'-[(2-Propyl-1,4,5,6-te trahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide or a salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc